Emerging therapeutic options for sporadic inclusion body myositis

Sporadic inclusion body myositis is the most common inflammatory muscle disorder preferentially affecting males over the age of 40 years. Progressive muscle weakness of the finger flexors and quadriceps muscles results in loss of independence with activities of daily living and eventual wheelchair dependence. Initial signs of disease are often overlooked and can lead to mis- or delayed diagnosis. The underlying cause of disease is unknown, and disease progression appears refractory to available treatment options. This review discusses the clinical presentation of inclusion body myositis and the current efforts in diagnosis, and focuses on the current state of research for both nonpharmacological and pharmacological treatment options for this patient group.

• Publication year

  2015

• Venue

  Therapeutics and Clinical Risk Management

• Publication date

  2015-09-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/TCRM.S65368PMID 26445546PMCID 4590682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches.

  2015cited by this paper
• Demographic and clinical features of inclusion body myositis in north America

  2015cited by this paper
• The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis

  2015cited by this paper
• A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

  2015cited by this paper
• 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands.

  2015cited by this paper
• Magnetic resonance imaging pattern recognition in sporadic inclusion‐body myositis

  2015cited by this paper
• Cytosolic 5′‐Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases

  2015cited by this paper
• Incidence and prevalence of inflammatory myopathies: a systematic review.

  2015cited by this paper
• Discovery of new biomarkers of idiopathic inflammatory myopathy.

  2015cited by this paper
• Mitochondrial and inflammatory changes in sporadic inclusion body myositis

  2015cited by this paper
• Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases

  2015cited by this paper
• Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken

  2015cited by this paper
• Inclusion body myositis.

  2014cited by this paper
• Cytoplasmic 5′‐nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility

  2014cited by this paper
• Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis.

  2014cited by this paper
• Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials.

  2014cited by this paper
• Functional relevance of mitochondrial abnormalities in sporadic inclusion body myositis.

  2014cited by this paper
• Treatment of sporadic inclusion body myositis with bimagrumab

  2014cited by this paper
• Dysphagia Due to Inclusion Body Myositis

  2014cited by this paper
• The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis.

  2014cited by this paper
• Inclusion body myositis: update

  2014cited by this paper
• Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis.

  2014cited by this paper
• Sporadic inclusion body myositis: new insights and potential therapy.

  2014cited by this paper
• Evaluation and construction of diagnostic criteria for inclusion body myositis

  2014cited by this paper
• Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis.

  2013cited by this paper
• Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis

  2013cited by this paper
• Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.

  2013cited by this paper
• Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features

  2013cited by this paper
• Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies

  2013cited by this paper
• Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis

  2013cited by this paper
• Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies

  2013cited by this paper
• Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis

  2013cited by this paper
• Biomarkers of inclusion body myositis

  2013cited by this paper
• The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.

  2013cited by this paper
• Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositis.

  2013cited by this paper
• International Workshop : Inclusion Body Myositis , 2 – 4 December 2011 , Naarden , The Netherlands

  2013cited by this paper
• An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

  2013cited by this paper
• Left ventricular hypertrabeculation/noncompaction coincidentally found in sporadic inclusion body myositis.

  2013cited by this paper
• Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up

  2013influential reference
• Inclusion body myositis coexisting with hypertrophic cardiomyopathy: an autopsy study.

  2012cited by this paper
• Hand function in 45 patients with sporadic inclusion body myositis.

  2012cited by this paper
• Knee extensor strength exhibits potential to predict function in sporadic inclusion‐body myositis

  2012cited by this paper
• Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis.

  2012cited by this paper
• High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes.

  2012cited by this paper
• Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.

  2012cited by this paper
• TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis.

  2012cited by this paper
• Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?

  2012cited by this paper
• Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders

  2012cited by this paper
• Gene therapy for muscular dystrophy: lessons learned and path forward.

  2012cited by this paper
• Prognosis and prognostic factors in sporadic inclusion body myositis

  2012cited by this paper
• Dilated cardiomyopathy and inclusion body myositis

  2012cited by this paper
• Mesoangioblasts of inclusion-body myositis: a twofold tool to study pathogenic mechanisms and enhance defective muscle regeneration

  2011cited by this paper
• Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis.

  2011influential reference
• Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex.

  2011cited by this paper
• A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

  2011cited by this paper
• Long-term observational study of sporadic inclusion body myositis.

  2011cited by this paper
• Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008.

  2010cited by this paper
• Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximab

  2010cited by this paper
• Cardiac involvement in sporadic inclusion-body myositis.

  2010cited by this paper
• Theories of the Pathogenesis of Inclusion Body Myositis

  2010cited by this paper
• Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers.

  2010cited by this paper
• In AβPP‐overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AβPP751 and GSK3β activation: effects mitigated by lithium and apparently relevant to sporadic inclusion‐body myositis

  2010cited by this paper
• Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype.

  2009cited by this paper
• Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

  2009cited by this paper
• Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

  2009cited by this paper
• Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β

  2008cited by this paper
• Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota.

  2008cited by this paper
• A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

  2008cited by this paper
• Dysphagia in Inclusion Body Myositis: Clinical Features, Management, and Clinical Outcome

  2008cited by this paper
• Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

  2008influential reference
• Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis.

  2008cited by this paper
• Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM

  2008cited by this paper
• Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features.

  2007cited by this paper
• MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle

  2006cited by this paper
• Epidemiology of neuroimmunological diseases

  2006cited by this paper
• Pilot trial of etanercept in the treatment of inclusion-body myositis

  2006cited by this paper
• Adult‐onset inflammatory myopathy: North Canterbury experience 1989–2001

  2005cited by this paper
• Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction.

  2003cited by this paper
• Intravenous immunoglobulin for dysphagia of inclusion body myositis

  2002cited by this paper
• Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

  2002cited by this paper
• Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis.

  2002cited by this paper
• A prospective natural history study of inclusion body myositis

  2001cited by this paper
• Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone

  2001cited by this paper
• Patterns of muscle involvement in inclusion body myositis: Clinical and magnetic resonance imaging study

  2001cited by this paper
• Treatment of inclusion-body myositis with IVIg

  1997cited by this paper
• Inclusion body myositis and myopathies

  1997cited by this paper
• Inclusion body myositis and myopathies

  1995cited by this paper
• Inclusion body myositis

  1995cited by this paper
• Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases

  1994cited by this paper
• Inclusion body myositis: analysis of 32 cases.

  1992cited by this paper
• Inclusion body myositis. Observations in 40 patients.

  1989cited by this paper
• Transgenic expression of (cid:1) -APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology

  year unknowncited by this paper
• submit your manuscript | www.dovepress.com

  year unknowncited by this paper

• Quadriceps and ankle weakness in inclusion body myositis: impact on descending balance control and rehabilitation strategies - a systematic review.

  2026cites this paper
• Whole‐body‐electro‐myostimulation for the care of inclusion body myositis—A case report

  2024cites this paper
• Inclusion body myositis

  2019cites this paper
• Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

  2019cites this paper
• A cross-sectional study of hand function in inclusion body myositis: Implications for functional rating scale.

  2019cites this paper
• Botulinum toxin alleviates dysphagia of patients with inclusion body myositis.

  2017cites this paper
• A recipe for myositis: nuclear factor κB and nuclear factor of activated T-cells transcription factor pathways spiced up by cytokines

  2017cites this paper
• Outpatient Physical Therapy Evaluation and Treatment of a Patient Diagnosed with Sporadic Inclusion Body Myositis: A Case Study

  2017cites this paper
• Multicenter questionnaire survey for sporadic inclusion body myositis in Japan

  2016cites this paper
• Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016.

  2016cites this paper